Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Breast Neoplasms 3Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Mediastinal Neoplasms 1Lung Neoplasms 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 1

Interventions

Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × 130-nm albumin-bound paclitaxel × Clear all
NCT04435652 2020-06-17

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Unknown
492 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡